DoxyHEXAL® tabs 100 mg Tabletten ( DrugBank: - )

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
28全身性アミロイドーシス1

28. 全身性アミロイドーシス

臨床試験数 : 261 /  薬物数 : 276 - (DrugBank : 81) / 標的遺伝子数 : 68 - 標的パスウェイ数 : 178
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1EUCTR2017-002210-31-DE
(EUCTR)		31/05/201924/01/2019An allocation by random phase II/III trial of doxycycline in comparison to standard therapy in newly-diagnosed cardiac AL amyloidosis patients with bortezomib-based therapyA randomized phase II/III trial of doxycycline vs. standard supportive therapy in newly-diagnosed cardiac AL amyloidosis patients undergoing bortezomib-based therapy - ReDox Light chain (AL) amyloidosis is a protein conformational disease, caused by a small bone marrow plasma cell clone producing light chains (LCs) that undergo conformational changes, aggregate and deposit in tissues in the form of amyloid fibrils. This process causes dysfunction of the organs involved and leads to death if not effectively treated.;Therapeutic area: Not possible to specifyTrade Name: DoxyHEXAL® tabs 100 mg Tabletten
Product Name: DoxyHEXAL® tabs 100 mg Tabletten
INN or Proposed INN: DOXYCYCLINE		Amyloid Center - Biotechnology Research Laboratories Policlinico San MatteoNULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes		120 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noCanada;Turkey;Germany